SG11201909115WA - Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof - Google Patents

Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Info

Publication number
SG11201909115WA
SG11201909115WA SG11201909115WA SG11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA
Authority
SG
Singapore
Prior art keywords
street
international
compounds
gsk3
cambridge
Prior art date
Application number
Other languages
English (en)
Inventor
Florence Wagner
Michel Weiwer
Arthur Campbell
Joshua Sacher
Edward Holson
Brian Lucas
Teyu Chen
Original Assignee
Broad Inst Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc, Biogen Ma Inc filed Critical Broad Inst Inc
Publication of SG11201909115WA publication Critical patent/SG11201909115WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201909115W 2017-04-05 2018-04-05 Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof SG11201909115WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481981P 2017-04-05 2017-04-05
PCT/US2018/026339 WO2018187630A1 (en) 2017-04-05 2018-04-05 Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
SG11201909115WA true SG11201909115WA (en) 2019-10-30

Family

ID=63712671

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909115W SG11201909115WA (en) 2017-04-05 2018-04-05 Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Country Status (14)

Country Link
US (2) US11203601B2 (pt)
EP (1) EP3606528B1 (pt)
JP (1) JP7157075B2 (pt)
KR (1) KR20190136063A (pt)
CN (1) CN110958882B (pt)
AU (1) AU2018249558A1 (pt)
BR (1) BR112019020810A2 (pt)
CA (1) CA3058198A1 (pt)
CO (1) CO2019012324A2 (pt)
EA (1) EA201992359A1 (pt)
IL (1) IL269701A (pt)
MX (1) MX2019011987A (pt)
SG (1) SG11201909115WA (pt)
WO (1) WO2018187630A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043853T2 (hu) 2012-10-12 2019-09-30 Broad Inst Inc GSK3 inhibitorok és eljárások azok alkalmazására
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
WO2023246820A1 (zh) * 2022-06-20 2023-12-28 上海优替济生生物医药有限公司 体外诱导干细胞样记忆细胞的化合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722416A1 (de) 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH05157164A (ja) 1991-12-03 1993-06-22 Aisin Aw Co Ltd 車両用自動変速機のサーボ油圧制御装置
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
HUT74104A (en) 1993-04-08 1996-11-28 Du Pont Merck Pharma Novel polycyclic derivatives and pharmaceutical compositions containing them
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
KR20030076650A (ko) 2001-02-02 2003-09-26 미쯔비시 웰 파마 가부시키가이샤 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
RS51351B (en) 2005-07-20 2011-02-28 Aventis Pharma S.A. 1,4-DIHYDROPYRIDINE-CONDENSED HTEROCYCLES, PROCEDURES FOR THEIR PRODUCTION, USE AND THE COMPOSITIONS CONTAINING THEM
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US8778986B1 (en) 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
US9265764B2 (en) 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
HUE043853T2 (hu) 2012-10-12 2019-09-30 Broad Inst Inc GSK3 inhibitorok és eljárások azok alkalmazására
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
WO2015087996A1 (ja) 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
KR101602559B1 (ko) 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
KR20170044144A (ko) 2014-09-05 2017-04-24 메르크 파텐트 게엠베하 암 치료를 위한 인돌아민-2,3-디옥시게나제(ido) 길항제로서 시클로헥실-에틸 치환된 디아자- 및 트리아자-트리시클릭 화합물

Also Published As

Publication number Publication date
CN110958882A (zh) 2020-04-03
MX2019011987A (es) 2020-07-14
US20220112216A1 (en) 2022-04-14
US11203601B2 (en) 2021-12-21
CN110958882B (zh) 2023-08-29
KR20190136063A (ko) 2019-12-09
JP2020516616A (ja) 2020-06-11
IL269701A (en) 2019-11-28
US20200109154A1 (en) 2020-04-09
JP7157075B2 (ja) 2022-10-19
WO2018187630A1 (en) 2018-10-11
CA3058198A1 (en) 2018-10-11
EP3606528A4 (en) 2020-12-23
EA201992359A1 (ru) 2020-03-12
WO2018187630A8 (en) 2019-01-03
AU2018249558A1 (en) 2019-11-07
CO2019012324A2 (es) 2020-05-15
EP3606528A1 (en) 2020-02-12
BR112019020810A2 (pt) 2020-04-28
EP3606528B1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
SG11201909710XA (en) Indole ahr inhibitors and uses thereof
SG11201808582RA (en) Pyrrolotriazine compounds as tam inhibitors
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201906883SA (en) Methods for the administration of certain vmat2 inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805380YA (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201909115WA (en) Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors